Delving into the Latest Updates on Denosumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

anti-RANKL antibody, Denosumab (Genetical Recombination), Denosumab (genetical recombination) (JAN)

+ [14]

Target

RANKL

Action

inhibitors

Mechanism

RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesEndocrinology and Metabolic Disease+ [6]

Active Indication

Glucocorticoid-induced osteoporosisHumoral Hypercalcemia of MalignancyRheumatoid Arthritis+ [14]

Inactive Indication

Advanced breast cancerAdvanced cancerAneurysmal Bone Cysts+ [46]

Originator Organization

Amgen, Inc.

Active Organization

Amgen Ltd.

Amgen, Inc.Amgen Europe BV

+ [5]

Inactive Organization

Celgene Corp.

GlaxoSmithKline (China) Investment Co., Ltd.

GSK Plc

+ [1]

License Organization

Dr. Reddy's Laboratories Ltd.

Amgen, Inc.

+ [10]

Drug Highest PhaseApproved

First Approval Date

European Union (26 May 2010),

Bone Diseases, MetabolicFractures, BoneOsteoporosis, Postmenopausal

RegulationOrphan Drug (United States), Conditional marketing approval (China), Orphan Drug (Japan), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 94568L

Source: *****

Sequence Code 143522H

Source: *****

Osteoporosis requires life-long management. This involves the use of different drugs in various sequences followed by long-term maintenance therapy. This review highlights the important transitions among osteoporosis therapies and outlines a strategy of intermittent bisphosphonate therapy for long-term maintenance.

RECENT FINDINGS:

Over the past few years, the effects and limitations of long-term treatment with bisphosphonates and denosumab have become apparent as have several key factors in the sequential use of anti-remodeling drugs and osteoanabolic agents. Strategies for transitions from estrogen, bisphosphonates, denosumab and the bone-forming drugs will be discussed, based on extant evidence, clinical experience and expert opinion. By appropriate selection of both the initial and subsequent drugs for the prevention and treatment of osteoporosis, therapeutic benefits can be optimized and safety issues minimized. Developing a strategy for long-term maintenance of the benefits of the initial therapies can provide a life plan for managing patients with osteoporosis.

01 Dec 2025·Current Osteoporosis Reports

Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity

Review

Author: Paccou, Julien ; Karam, Léa

Abstract:

Purpose:

This review focuses on recent findi+ngs regarding the management of adverse skeletal effects following weight loss in people living with obesity (PwO). We summarize the guidelines provided by various societies for the prevention and treatment of osteoporosis resulting from bariatric surgery. Next, we discuss the use of traditional antiosteoporosis medications in this population.

Recent Findings:

Guidelines for preventing and treating osteoporosis resulting from bariatric surgery have been recently provided by various societies setting specific treatment criteria for postmenopausal women and men aged ≥ 50 years, based on the occurrence of fragility fractures and/or T-score thresholds. Several studies have highlighted the positive effects of lifestyle changes in preventing high-turnover bone loss; however, data on fracture outcomes are currently unavailable. It is generally accepted that following bariatric procedures, sufficient intake of calcium, vitamin D, and protein, along with regular exercise incorporating progressive, supervised resistance training, is crucial to counteract negative impacts on bone. Regarding the need for medications to combat osteoporosis, most societies recommend zoledronic acid as the preferred choice. This preference is due to the problems associated with oral bisphosphonates, including poor tolerance and absorption issues. Denosumab is typically considered the second choice when bisphosphonates are not suitable or well tolerated. Two randomized controlled studies have recently demonstrated the effectiveness and safety of zoledronic acid and denosumab in addressing high-turnover bone loss.

Summary:

Although guidelines exist for managing skeletal health before and after bariatric surgery, more research is required to validate these recommendations and the use of anti-osteoporosis medications.

01 Dec 2025·European Journal of Trauma and Emergency Surgery

Effectiveness of a co-management program with internal medicine on hip fracture patients at a regional hospital in northwest Spain. Co-inter-Monf study

Article

Author: Marchán-López, Álvaro ; Cambón Cotelo, Javier ; Rodríguez Álvarez, Ana ; Quevedo Vila, Victor ; López-Castro, José

BACKGROUND:

Hip fractures represent a serious public health problem with a high burden of mortality, morbidity, and resource use. Co-management has proven to enhance the clinical outcomes of hip fracture patients hospitalized in various settings.

AIM:

This study aims to evaluate whether the previously observed benefits of co-management can be achieved when such a program is implemented in a rural-based district hospital.

METHODS:

A prospective, single-center observational study was conducted on hip fracture patients hospitalized for hip fracture. Patients were either co-managed by an internal medicine specialist with part-time dedication or not co-managed. The study was conducted in a rural hospital located in Galicia, Northwestern Spain, which serves a population of 45,000.

RESULTS:

A total of 207 patients were included in the study, of whom 97 received co-management. The majority of the patients who were co-managed were female (69.1%) and had a median age of 88 years (interquartile range 83-92). The study showed a high burden of comorbidity with a median Charlson index of 6 points, along with high prevalence rates of dementia (46%), functional disability (50%), and chronic anticoagulant therapy (25%). Despite no differences in age, sex, or preadmission cognitive or functional status, the study found lower 30-day postdischarge mortality in co-managed patients (9.3%) compared with the 110 controls (20.0%, p = 0.049). The prevalence of osteoporosis treatment, both calcium/vitamin D (87.8% vs. 60.7%, p < 0.001) and bisphosphonates/denosumab/teriparatide (42.4% vs. 15.7%, p < 0.001), was higher in the co-managed patients at 30 days after discharge. No differences were observed between the two groups in terms of in-hospital mortality and length of stay.

CONCLUSIONS:

The implementation of internal medicine co-management for hip fracture patients resulted in enhanced outcomes, particularly in the reduction of mortality within 30 days of discharge as well as in the prevalence of osteoporosis treatment.

237

News (Medical) associated with Denosumab

02 Jun 2025

·pipelinereview.com

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

BASEL, Switzerland I June 2, 2025 I Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, has announced that WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are available to patients in the US starting today. WYOST® and Jubbonti® are the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of the reference medicines XGEVA®* (denosumab) and Prolia®* (denosumab), respectively.[2,3] This launch builds on Sandoz established leadership in biosimilars and oncology, dating back to the introduction of the first biosimilar in the US in 2015. WYOST® and Jubbonti® are key biosimilar value drivers that are integral to the Sandoz growth strategy, representing a significant step forward in advancing the Company’s ambition to be the biosimilar leader in the US. Keren Haruvi, President Sandoz North America, said: “Denosumab is a vital medicine for conditions such as osteoporosis and cancer-related skeletal events. Providing an additional high-quality, cost-effective treatment option helps improve access and affordability for US patients.” WYOST® and Jubbonti® have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines. WYOST® and Jubbonti® are approved as interchangeable with the reference medicines for all indications. WYOST® and Jubbonti® will be launching with an established Q code. Sandoz is providing comprehensive support resources for patients who are prescribed WYOST® and Jubbonti®, including reimbursement and financial support. Claire Gill, Chief Executive Officer, Bone Health and Osteoporosis Foundation, said: “Bone loss and cancer-related skeletal complications can have a profound impact on patients’ lives, but access to effective treatments has often been impacted by cost. With the introduction of new biosimilar options, patients now have access to more treatments they need and deserve.” Bone metastases occur when cancer cells move away from the original tumor site and into the bone, weakening its structure and often causing significant skeletal-related events (SREs) such as pain and fractures.[4] They are most common in patients with breast, prostate, lung, kidney and thyroid cancers and approximately 330,000 people in the US are living with bone metastases.[4] Osteoporosis is a condition that develops when bone mineral density and bone mass decrease causing the bones to become thinner, weaker and more likely to break.[5] Over 10 million US adults 50 years of age or older live with osteoporosis, with over 43 million at risk due to low bone mass.[1,5] Half of all women and a quarter of all men over the age of 50 will break a bone due to osteoporosis.[6] *XGEVA® and Prolia® are registered trademarks of Amgen Inc. About WYOST® (denosumab-bbdz) WYOST® 120 mg/1.7 mL (70 mg/mL) injection has been approved by the FDA as interchangeable with the reference medicine, a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue).[3,7] WYOST® is indicated in the US to prevent SREs in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy.[7] This is not the complete list of all the safety information for Wyost. Please click to see full Prescribing Information for Wyost. About Jubbonti® (denosumab-bbdz) Jubbonti® 60 mg/1 mL injection has been approved by the FDA as interchangeable with the reference medicine, a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue).[2,8] Jubbonti® is indicated in the US to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.[8] This is not the complete list of all the safety information for Jubbonti. Please click to see full Prescribing Information for Jubbonti. REFERENCES [1] Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or Low Bone Mass in Older Adults: United States, 2017–2018. Centers for Disease Control and Prevention. 2021;405. Available at: https://www-cdc-gov.libproxy1.nus.edu.sg/nchs/products/databriefs/db405.htm [Last accessed: June 2025] [2] Food and Drug Administration. Prolia® (Ustekinumab): Medication Guide. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125320s213lbl.pdf [Last accessed: June 2025] [3] Food and Drug Administration. XGEVA® (Ustekinumab): Medication Guide. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.pdf [Last accessed: June 2025] [4] Moffitt Cancer Center. Bone Metastasis. Available at: https://www.moffitt.org/cancers/bone-metastasis/ [Last accessed: June 2025] [5] Food and Drug Administration. Osteoporosis. Available at: https://www.fda.gov/consumers/womens-health-topics/osteoporosis [Last accessed: June 2025] [6] American Academy of Orthopaedic Surgeons. Osteoporosis. Available at: https://orthoinfo.aaos.org/en/diseases–conditions/osteoporosis/ [Last accessed: June 2025] [7] WYOST®. Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761362s000lbl.pdf [Last accessed: June 2025] [8] Jubbonti®. Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761362s000lbl.pdf [Last accessed: June 2025] ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. SOURCE: Sandoz

Drug Approval

20 May 2025

·pharma.economictimes.indiatimes.com

DRL gears up for biosimilar push, consumer health growth post record FY25

New Delhi: Dr Reddy’s Laboratories (DRL) has gained 5.5 per cent on bourses in six trading sessions since declaring the fourth quarter numbers compared with a 3.6 per cent increase in the BSE Healthcare index. The company reported double-digit growth in revenue and net profit for the March 2024 quarter. Revenue growth was driven by the acquisition of Nicotine Replacement Therapy (NRT) portfolio from UK’s Haleon in June 2024. The next phase of growth once Revlimid sales taper after the drug goes off patent in January 2026, will be driven by biosimilars and Semaglutide portfolios. The company is likely to post double-digit revenue growth for FY26 but EBITDA margin may shrink to 25 per cent from 28 per cent in FY25 due to tapering sales of gRevlimid. Given this, analysts have reduced the target prices of the stock by 6-14 per cent. Despite cuts, the target prices were 6-18 per cent higher than the stock price on May 09 when the quarterly result was out and continue to remain above Monday’s closing price of Rs1,219. Also, biosimilars and semaglutide offer future growth potential thereby supporting the stock price. On a year-on-year basis, DRL’s revenue and net profit rose 20 per cent and 21 per cent year-on-year to Rs8,506 crore and Rs1,587 crore in the March 2025 quarter, respectively. Excluding NRT sales, revenue growth slowed to 12 per cent. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased for the fifth consecutive quarter to Rs2,474.9 crore, a year-on-year 32.2 per cent growth. Full-year R&D investment was Rs2,738 crores, up 20 per cent year-on-year. However, its proportion in revenue fell by 118 basis points to 8.5 per cent. The company expects to retain the R&D expenditure in a similar range even after the gRevlimid sales normalise. It will be driven by building a differentiated pipeline spanning small molecules, biosimilars, and complex generics including peptides and cancer therapy. DRL completed 95 global generic filings, bringing the total for FY25 to 249. The company is about to launch GLP-1 (Semaglutide) globally during the current calendar year. Abatacept, a medication used to treat rheumatoid arthritis and other autoimmune diseases, is into Phase III and the company plans to submit it for approval towards the end of 2025. The biosimilar segment remains a key growth driver in the coming quarters. According to Axis Securities, the company’s two biosimilar drugs slated for launch in Europe have the potential to contribute $40–50 million in sales in FY26. Additionally, osteoporosis drug Denosumab, scheduled for launch in FY27, is estimated to generate $50 million in annual sales. The brokerage has cut the target price to Rs1,250 from Rs1,450 earlier, valuing the company at 17 times FY27 expected earnings. Elara Capital has lowered its FY26 earnings estimate 10 per cent in anticipation of lower gRevlimid sales while raising FY27 estimate by 4 per cent in anticipation of margin stability. The brokerage has highlighted price erosion in the US market and delay in product approvals as major risks to its forecast. By Snehal Mergu ,

Phase 3BiosimilarDrug ApprovalAcquisitionFinancial Statement

20 May 2025

·pharma.economictimes.indiatimes.com

DRL gears up for biosimilar push, consumer health growth post record FY25

New Delhi: Dr Reddy’s Laboratories (DRL) has gained 5.5 per cent on bourses in six trading sessions since declaring the fourth quarter numbers compared with a 3.6 per cent increase in the BSE Healthcare index. The company reported double-digit growth in revenue and net profit for the March 2024 quarter. Revenue growth was driven by the acquisition of Nicotine Replacement Therapy (NRT) portfolio from UK’s Haleon in June 2024. The next phase of growth once Revlimid sales taper after the drug goes off patent in January 2026, will be driven by biosimilars and Semaglutide portfolios. The company is likely to post double-digit revenue growth for FY26 but EBITDA margin may shrink to 25 per cent from 28 per cent in FY25 due to tapering sales of gRevlimid. Given this, analysts have reduced the target prices of the stock by 6-14 per cent. Despite cuts, the target prices were 6-18 per cent higher than the stock price on May 09 when the quarterly result was out and continue to remain above Monday’s closing price of Rs1,219. Also, biosimilars and semaglutide offer future growth potential thereby supporting the stock price. On a year-on-year basis, DRL’s revenue and net profit rose 20 per cent and 21 per cent year-on-year to Rs8,506 crore and Rs1,587 crore in the March 2025 quarter, respectively. Excluding NRT sales, revenue growth slowed to 12 per cent. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased for the fifth consecutive quarter to Rs2,474.9 crore, a year-on-year 32.2 per cent growth. Full-year R&D investment was Rs2,738 crores, up 20 per cent year-on-year. However, its proportion in revenue fell by 118 basis points to 8.5 per cent. The company expects to retain the R&D expenditure in a similar range even after the gRevlimid sales normalise. It will be driven by building a differentiated pipeline spanning small molecules, biosimilars, and complex generics including peptides and cancer therapy. DRL completed 95 global generic filings, bringing the total for FY25 to 249. The company is about to launch GLP-1 (Semaglutide) globally during the current calendar year. Abatacept, a medication used to treat rheumatoid arthritis and other autoimmune diseases, is into Phase III and the company plans to submit it for approval towards the end of 2025. The biosimilar segment remains a key growth driver in the coming quarters. According to Axis Securities, the company’s two biosimilar drugs slated for launch in Europe have the potential to contribute $40–50 million in sales in FY26. Additionally, osteoporosis drug Denosumab, scheduled for launch in FY27, is estimated to generate $50 million in annual sales. The brokerage has cut the target price to Rs1,250 from Rs1,450 earlier, valuing the company at 17 times FY27 expected earnings. Elara Capital has lowered its FY26 earnings estimate 10 per cent in anticipation of lower gRevlimid sales while raising FY27 estimate by 4 per cent in anticipation of margin stability. The brokerage has highlighted price erosion in the US market and delay in product approvals as major risks to its forecast. By Snehal Mergu ,

Phase 3BiosimilarDrug ApprovalAcquisitionFinancial Statement

100 Deals associated with Denosumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03684	Denosumab	M05BX04	DB06643

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glucocorticoid-induced osteoporosis	United States	Amgen, Inc.	18 May 2018
Humoral Hypercalcemia of Malignancy	United States	Amgen, Inc.	04 Jan 2018
Rheumatoid Arthritis	Japan	Daiichi Sankyo Co., Ltd.	03 Jul 2017
Bone Cancer	Japan	Amgen, Inc.	18 Jan 2012
Multiple Myeloma	Japan	Amgen, Inc.	18 Jan 2012
Bone Diseases	European Union	Amgen Europe BV	13 Jul 2011
Bone Diseases	Iceland	Amgen Europe BV	13 Jul 2011
Bone Diseases	Liechtenstein	Amgen Europe BV	13 Jul 2011
Bone Diseases	Norway	Amgen Europe BV	13 Jul 2011
Giant Cell Tumor of Bone	European Union	Amgen Europe BV	13 Jul 2011
Giant Cell Tumor of Bone	Iceland	Amgen Europe BV	13 Jul 2011
Giant Cell Tumor of Bone	Liechtenstein	Amgen Europe BV	13 Jul 2011
Giant Cell Tumor of Bone	Norway	Amgen Europe BV	13 Jul 2011
Bone metastases	United States	Amgen, Inc.	18 Nov 2010
Osteoporosis	Australia	Amgen Australia Pty Ltd.	07 Jun 2010
Bone Diseases, Metabolic	European Union	Amgen Europe BV	26 May 2010
Bone Diseases, Metabolic	Iceland	Amgen Europe BV	26 May 2010
Bone Diseases, Metabolic	Liechtenstein	Amgen Europe BV	26 May 2010
Bone Diseases, Metabolic	Norway	Amgen Europe BV	26 May 2010
Fractures, Bone	European Union	Amgen Europe BV	26 May 2010

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atypical anorexia nervosa	Phase 3	United States	Amgen, Inc.	25 Oct 2017
Feeding and Eating Disorders	Phase 3	United States	Amgen, Inc.	25 Oct 2017
Osteogenesis Imperfecta	Phase 3	United States	Amgen, Inc.	24 Jun 2015
Osteogenesis Imperfecta	Phase 3	Australia	Amgen, Inc.	24 Jun 2015
Osteogenesis Imperfecta	Phase 3	Belgium	Amgen, Inc.	24 Jun 2015
Osteogenesis Imperfecta	Phase 3	Bulgaria	Amgen, Inc.	24 Jun 2015
Osteogenesis Imperfecta	Phase 3	Canada	Amgen, Inc.	24 Jun 2015
Osteogenesis Imperfecta	Phase 3	Czechia	Amgen, Inc.	24 Jun 2015
Osteogenesis Imperfecta	Phase 3	France	Amgen, Inc.	24 Jun 2015
Osteogenesis Imperfecta	Phase 3	Germany	Amgen, Inc.	24 Jun 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Giant Cell Tumor of Bone Neoadjuvant \| Adjuvant	31	Denosumab	mjfqqnhpkx(bcuzwjeosx) = hvsosrqsfn ogrvxxhken (kiftsuobhw, 1 - 150) View more	-	30 May 2025
ASCO2025	Not Applicable	Bone metastases	340	Denosumab monotherapy	zyvqdhbqdu(lxdbbngzuu): P-Value = 0.027	Positive	30 May 2025
				Bisphosphonate switching to Denosumab
ASCO2025	Not Applicable	Giant Cell Tumors	-	Denosumab	dxhimwtypq(ktrzfggola) = tzososxdze xynwpxuual (vcxutfrghe ) View more	Positive	30 May 2025
				denosumab (Control Group)	dxhimwtypq(ktrzfggola) = udfokpshyk xynwpxuual (vcxutfrghe ) View more
ESMO_BC2025	Not Applicable	Premenopausal breast cancer Adjuvant	69	Denosumab	myourcvhxs(jmgmywbkbd) = One ONJ case occurred (1.4 %) with no fractures reported pmiqgxiuvi (byxwciglii )	Positive	14 May 2025
PS1717 (EHA2025)	Not Applicable	Multiple Myeloma urinary N-terminal telopeptide of type 1 collagen \| bone alkaline phosphatase \| serum C-terminal telopeptide of type 1 collagen	236	Narlumosbart 120 mg SC Q4W	kqkeysqboy(fornfhcxcr) = efxttkpoma usaxtchxfu (nhdhulpijr ) View more	Positive	14 May 2025
				Denosumab 120 mg SC Q4W	kqkeysqboy(fornfhcxcr) = bwjbfyfbkl usaxtchxfu (nhdhulpijr ) View more
ESMO_BC2025	Not Applicable	Second line BRCA1/2	1,399	Denosumab	tkqzmosulv(luumjtjsgg) = mhiilxpqej nagijtcovw (lorywqkxkk, 24 - NR)	Positive	14 May 2025
				denosumab (BRCA1/2-mutated HR+/HER2- bone metastatic breast cancer patients)	tkqzmosulv(luumjtjsgg) = gidkfdodzw nagijtcovw (lorywqkxkk, 9 - 27)
NCT02299817 (Pubmed \| BMC Res Notes)	Phase 2	Osteolysis	-	Denosumab	buqylmmiqo(nedkaauhmi) = hwrmfsghmg qrdqujgiwg (akmudinecc )	Positive	08 Apr 2025
				Placebo	buqylmmiqo(nedkaauhmi) = iyyagtbmqb qrdqujgiwg (akmudinecc )
ESMO_SRC2025	Not Applicable	Giant Cell Tumor of Bone	-	Denosumab	pcaxezlbgh(ggsizkyzzf) = msuaofvekp lbuhovjuid (wutupfsncf ) View more	Positive	21 Mar 2025
				denosumab (Control Group)	pcaxezlbgh(ggsizkyzzf) = orxdirlial lbuhovjuid (wutupfsncf ) View more
NCT00330759 \| NCT00321464 \| NCT00321620 (Study 20050103, FDA_CDER) Manual	Phase 3	Bone metastases	-	Denosumab (Study 20050136 Metastatic Breast Cancer)	lwilzcxbla(xwyzumpvsj) = rbenutvubi jlrpddqaom (wchrfmqtks ) View more	Positive	28 Feb 2025
				Zoledronic Acid (Study 20050136 Metastatic Breast Cancer)	lwilzcxbla(xwyzumpvsj) = aekjcwjarm jlrpddqaom (wchrfmqtks ) View more
NCT00396279 \| NCT00680992 (Study 20062004, FDA_CDER) Manual	Phase 2	Giant Cell Tumor of Bone	187	Denosumab 120 mg	avoifkghml(bbemhupmje) = mtituaifcl asjrveauqy (lekjloqivz, 19 - 32) View more	Positive	28 Feb 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Denosumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation